Cargando…

Ibrutinib is not an effective drug in primografts of TCF3-PBX1

AIM: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive B-cell precursor acute lymphoblastic leuke...

Descripción completa

Detalles Bibliográficos
Autores principales:	van de Ven, Cesca, Boeree, Aurélie, Stalpers, Femke, Zwaan, C. Michel, Den Boer, Monique L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2020
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306596/ https://www.ncbi.nlm.nih.gov/pubmed/32563910 http://dx.doi.org/10.1016/j.tranon.2020.100817

Ejemplares similares

Genetic features of B‐cell lymphoblastic lymphoma with TCF3‐PBX1
por: Shirai, Ryota, et al.
Publicado: (2021)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
por: Eldfors, S, et al.
Publicado: (2017)

Translocation junctions in TCF3-PBX1 acute lymphoblastic leukemia/lymphoma cluster near transposable elements
por: Rodić, Nemanja, et al.
Publicado: (2013)

A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report
por: Barbosa, Thayana Conceição, et al.
Publicado: (2018)

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia
por: Steeghs, Elisabeth M.P., et al.
Publicado: (2017)

PBX3 in Cancer
por: Morgan, Richard, et al.
Publicado: (2020)

Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment
por: Burmeister, Thomas, et al.
Publicado: (2023)

Characterization of a novel MEF2D-BCL9 fusion-positive acute lymphoblastic leukemia cell line
por: van Outersterp, Inge, et al.
Publicado: (2023)

Integrating copy number data of 64 iAMP21 BCP-ALL patients narrows the common region of amplification to 1.57 Mb
por: Hormann, Femke M., et al.
Publicado: (2023)

Underexpression of LINC00173 in TCF3/PBX1-Positive Cases Is Associated With Poor Prognosis in Children With B-Cell Precursor Acute Lymphoblastic Leukemia
por: May-Hau, Didier Ismael, et al.
Publicado: (2022)

P316: PRIORITIZING PRECISION MEDICINES IN PEDIATRIC BLOOD CANCER: EXPERIENCE OF THE DUTCH INDIVIDUALIZED THERAPY (ITHER) STUDY’S MOLECULAR TUMOR BOARD
por: Boer, Judith M., et al.
Publicado: (2023)

Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites
por: Thiaville, Michelle M., et al.
Publicado: (2012)

A (1;19) translocation involving TCF3-PBX1 fusion within the context of a hyperdiploid karyotype in adult B-ALL: a case report and review of the literature
por: Tirado, Carlos A, et al.
Publicado: (2015)

Targeting HOX/PBX dimers in cancer
por: Morgan, Richard, et al.
Publicado: (2017)

Correlation analysis of PBX family with immune invasion and drug sensitivity in colon adenocarcinoma
por: Chao, Guanqun, et al.
Publicado: (2023)

PBX Security and Forensics: A Practical Approach
por: Androulidakis, Iosif I
Publicado: (2013)

Co-occurrence of TCF3-PBX1 gene fusion, and chromosomal aberration in a pediatric pre-B cell acute lymphoblastic leukemia with clitoris swelling: A case report and literature review
por: He, Guo-qian, et al.
Publicado: (2021)

PBX3 is associated with proliferation and poor prognosis in patients with cervical cancer
por: Li, Hongfang, et al.
Publicado: (2017)

Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia
por: Steeghs, Elisabeth M. P., et al.
Publicado: (2019)

Evaluating the association of common PBX1 variants with type 2 diabetes
por: Duesing, Konsta, et al.
Publicado: (2008)

Paternal mosaicism for a novel PBX1 mutation associated with recurrent perinatal death: Phenotypic expansion of the PBX1‐related syndrome
por: Arts, Peer, et al.
Publicado: (2020)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Targeting HOX and PBX transcription factors in ovarian cancer
por: Morgan, Richard, et al.
Publicado: (2010)

Research progress of PBX1 in developmental and regenerative medicine
por: Chen, Hao, et al.
Publicado: (2023)

Comprehensive overview of the role of PBX1 in mammalian kidneys
por: Zou, Fei, et al.
Publicado: (2023)

Regulation of PBX3 expression by androgen and Let-7d in prostate cancer
por: Ramberg, Håkon, et al.
Publicado: (2011)

Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG)
por: Asai, Daisuke, et al.
Publicado: (2014)

PBX3 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition
por: Wang, Shuanhu, et al.
Publicado: (2016)

MiR-320 inhibits the growth of glioma cells through downregulating PBX3
por: Pan, Cuicui, et al.
Publicado: (2017)

Pbx homeodomain proteins pattern both the zebrafish retina and tectum
por: French, Curtis R, et al.
Publicado: (2007)

VoIP and PBX security and forensics: a practical approach
por: Androulidakis, Iosif I
Publicado: (2016)

Pbx4 is Required for the Temporal Onset of Zebrafish Myocardial Differentiation
por: Kao, Robert M., et al.
Publicado: (2015)

Biochemistry of the tale transcription factors PREP, MEIS, and PBX in vertebrates
por: Wellik, Deneen, et al.
Publicado: (2014)

Polymorphism in the PBX1 gene is related to cystinuria in Brazilian families
por: Reis, Sabrina T., et al.
Publicado: (2018)

PBX1 as Pioneer Factor: A Case Still Open
por: Grebbin, Britta M., et al.
Publicado: (2017)

Distinct requirements for Tcf3 and Tcf12 during oligodendrocyte development in the mouse telencephalon
por: Talley, Mary Jo, et al.
Publicado: (2023)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor
por: Adasme, Melissa F., et al.
Publicado: (2020)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation
por: Zhang, Qing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dkofrcuqk2l2g4ki13p3l0mn9l